Loading
Low Dose Benfotiamine / Alzheimer Disease / High Dose Benfotiamine · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registration for benfotiamine in early Alzheimer's disease with planned enrollment of 406 participants and a 72-week follow-up. No results have been posted in this registry record; the study is currently active but not recruiting.
Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Alzheimer Disease; age from 50 Years; to 89 Years. Intervention: Low Dose Benfotiamine; High Dose Benfotiamine. Compared with: Placebo — Placebo Comparator. n = 406. 47 sites: United States.
This is a Phase 2 clinical trial registration for benfotiamine in early Alzheimer's disease with planned enrollment of 406 participants and a 72-week follow-up. No results have been posted in this registry record; the study is currently active but not recruiting.
Phase 2A primary outcome is tolerability events rate; Phase 2B outcomes are cognitive and functional change, but no efficacy or safety data are reported.
The source did not state who this applies to in practice.
This is a Phase 2 trial registration with no posted results; it describes planned enrollment and outcomes but reports no efficacy or safety data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06223360). This is a study registration, not published results. Lead sponsor: Weill Medical College of Cornell University. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 406 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: DRUG: Low Dose Benfotiamine; DRUG: High Dose Benfotiamine; DRUG: Placebo. Primary outcome measures: Phase 2A: The rate of tolerability events (TEs). , Up to 72 weeks; Phase 2B: The primary cognitive endpoint is the within-participant change from baseline to 72 weeks compared between active arms (benfotiamine) and placebo on the Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13). , 72 weeks; Phase 2B: The primary functional endpoint is the within-participant change from baseline to 72 weeks compared between active arm (benfotiamine) and placebo on the Clinical Dementia Rating - Sum of Boxes (CDR-SB). , 72 weeks. Brief summary: The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.